|
Antibiotic
|
CLSI breakpointsa
(% of isolates)
|
PK/PD
|
|---|
|
Susceptible
|
Intermediate
|
Resistant
|
Susceptibility (% of isolates)
|
Breakpoint (μg/ml)
|
|---|
|
O. Penicillin
|
39.39
|
51.52
|
9.09
|
39.39
|
≤0.06
|
|
I. Penicillin
|
100
|
0
|
0
|
100
|
≤2
|
|
Amoxicillin
|
87.88
|
9.09
|
3.03
|
87.88
|
≤2
|
|
Cefotaxime
|
100
|
0
|
0
|
100
|
≤1
|
|
Ceftriaxone
|
96.97
|
3.03
|
0
|
96.97
|
≤1
|
|
Azithromycin
|
53.03
|
16.67
|
30.30
|
53.03
|
≤0.5
|
|
Erythromycin
|
66.67
|
3.03
|
30.30
|
66.67
|
≤0.25
|
|
Clarithromycin
|
71.21
|
0
|
28.79
|
71.21
|
≤0.25
|
|
Levofloxacin
|
75.76
|
24.24
|
0
|
75.76
|
≤2
|
|
Vancomycin
|
100
|
0
|
0
|
100
|
≤1
|
|
Trimethoprim-sulfamethoxazole
|
53.03
|
16.67
|
30.30
|
53.03
|
≤0.5
|
- Abbreviations: O oral, I intravenous
- aThe CLSI breakpoints used were ≤ 0.06 mg/L (susceptible), 0.12 to 1 mg/L (intermediate), and ≥ 2 mg/L (resistant) for oral penicillin and ≤ 2 mg/L (susceptible), 4 mg/L (intermediate), and ≥ 8 mg/L (resistant) for intravenous penicillin; ≤2 mg/L (susceptible), 4 mg/L (intermediate), and ≥ 8 mg/L (resistant) for amoxicillin; ≤1 mg/L (susceptible), 2 mg/L (intermediate), and ≥ 4 mg/L (resistant) for cefotaxime and ceftriaxone; ≤0.5 mg/L (susceptible), 1 mg/L (intermediate), and ≥ 2 mg/L (resistant) for azithromycin; ≤0.25 mg/L (susceptible), 0.5 mg/L (intermediate), and ≥ 1 mg/L (resistant) for erythromycin and clarithromycin; ≤2 mg/L (susceptible), 4 mg/L (intermediate), and ≥ 8 mg/L (resistant) for levofloxacin; ≤1 mg/L (susceptible) for vancomycin; and ≤ 0.5 mg/L (susceptible), 1–2 mg/L (intermediate), and ≥ 4 mg/L (resistant) for trimethoprim-sulfamethoxazole
